ABOUT THIS EPISODE
In this episode of The Oncology Insights Podcast, I speak with Dr. Timothy Burns, Professor of Medicine at The Ohio State University, about KRAS inhibitors within the evolving spectrum of systemic therapies for Non-Small Cell Lung Cancer (NSCLC). We discuss KRAS mutations, treatment resistance, immunotherapy combinations, biomarker testing, brain metastases, and his journey into lung cancer research. Listen now on all major platforms!
“KRAS mutations represent a major therapeutic target across cancers, creating opportunities for increasingly selective inhibitors designed around specific molecular alterations.”
Meet the guest: Dr. Timothy Burns is Professor of Medicine at The Ohio State University Comprehensive Cancer Center. With more than 89 publications and NCI R01 funding, his research advances targeted therapies for oncogene-driven NSCLC and brain metastases. He has led multiple clinical trials, including early-phase studies contributing to the approval of the KRAS G12C inhibitor sotorasib. Listen to Dr. Timothy Burns on The Oncology Insights Podcast, available on all major platforms.
Liked this one? Don’t stop now. Here’s what we think you’ll love!
What you will learn:
- (00:00) Highlight
- (01:50) Introduction
- (07:30) Targeting KRAS mutations
- (11:30) Resistance mechanisms
- (15:04) Therapy combinations
- (20:50) Brain metastases
- (28:53) Future KRAS strategies
- (36:17) Closing thoughts
The Oncology Insights Podcast is trusted and supported by innovative companies like:
- WiseVAs
- Elevate
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: The Oncology Insights Podcast
LinkedIn: The Oncology Insights Podcast
Instagram: The Oncology Insights Podcast
YouTube: The Oncology Insights Podcast
Facebook: The Oncology Insights Podcast
TikTok: The Oncology Insights Podcast
